OABI
OmniAb Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$220.07M
P/E Ratio
—
EPS
$-0.58
Beta
0.87
52W High
$2.29
52W Low
$1.22
50-Day MA
$1.76
200-Day MA
$1.78
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About OmniAb Inc.
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies through its proprietary OmniAb platform. This advanced technology enables the efficient discovery and optimization of high-quality therapeutics aimed at addressing a wide array of diseases. With a strategic emphasis on collaborations and partnerships, OmniAb is committed to accelerating drug development processes and enhancing the availability of breakthrough treatments. Led by a skilled management team and supported by a robust pipeline, the company is poised to capitalize on the growing opportunities within the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $18.67M |
| Gross Profit (TTM) | $18.36M |
| EBITDA | $-46.89M |
| Operating Margin | -147.40% |
| Return on Equity | -23.40% |
| Return on Assets | -13.00% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $1.85 |
| Price-to-Book | 0.83 |
| Price-to-Sales (TTM) | 11.79 |
| EV/Revenue | 10.14 |
| EV/EBITDA | -10.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -22.50% |
| Shares Outstanding | $144.78M |
| Float | $97.38M |
| % Insiders | 15.13% |
| % Institutions | 52.12% |
Analyst Ratings
Consensus ($7.33 target)
7
BuyData last updated: 4/9/2026